Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)

Antonella Radice, Barbara Trezzi, Umberto Maggiore, Francesca Pregnolato, Tiziana Stellato, Pietro Napodano, Davide Rolla, Gianpaola Pesce, Marco D'Amico, Domenico Santoro, Francesco Londrino, Federica Ravera, Giuseppe Ortisi, Renato Alberto Sinico

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of idiopathic membranous nephropathy (IMN). They can differentiate IMN from other glomerular diseases and primary from secondary forms of MN. Preliminary data suggest that anti-PLA2R antibody titer correlates with disease activity but more solid evidence is needed.To evaluate the performance of anti-PLA2R antibody for monitoring nephropathy activity, 149 anti-PLA2R antibody measurements were performed during the follow-up of 42 biopsy proven IMN consecutive patients. Patients were enrolled either at time of diagnosis (33 cases, inception cohort) or after diagnosis (9 patients, non-inception cohort).Anti-PLA2R detection was performed using the highly sensitive transfected cell-based indirect immunofluorescence (IIFT).Over the follow-up there was a linear time-trend of decreasing proteinuria (P <0.001), increasing serum albumin (P <0.001) and decreasing PLA2R antibody levels (P = 0.002). There was a statistically significant association between changes in PLA2R antibody levels and the clinical course of PLA2R-positive IMN. The positive PLA2R serum antibody status was linearly associated with increasing proteinuria and decreasing serum albumin over time, compared with negative antibody status. Moreover, the strong correlation between the clinical conditions and PLA2R antibody levels allowed the prediction of prevalence distribution of patients with active disease, partial and complete remission. Over the course of the follow-up, the probability of halving proteinuria increased 6.5 times after disappearance of PLA2R antibodies.Our data suggest that the serial evaluation of anti-PLA2R antibodies could help in optimal timing and duration of the immunosuppressive therapy, reducing over(under)-treatment and associated side-effects.

Original languageEnglish
Pages (from-to)146-154
Number of pages9
JournalAutoimmunity Reviews
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Phospholipase A2 Receptors
Membranous Glomerulonephritis
Autoantibodies
Antibodies
Proteinuria
Serum Albumin

Keywords

  • Autoantibody
  • Biomarker
  • Membranous nephropathy
  • Phospholipase A2 receptor
  • Proteinuria

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). / Radice, Antonella; Trezzi, Barbara; Maggiore, Umberto; Pregnolato, Francesca; Stellato, Tiziana; Napodano, Pietro; Rolla, Davide; Pesce, Gianpaola; D'Amico, Marco; Santoro, Domenico; Londrino, Francesco; Ravera, Federica; Ortisi, Giuseppe; Sinico, Renato Alberto.

In: Autoimmunity Reviews, Vol. 15, No. 2, 01.02.2016, p. 146-154.

Research output: Contribution to journalArticle

Radice, A, Trezzi, B, Maggiore, U, Pregnolato, F, Stellato, T, Napodano, P, Rolla, D, Pesce, G, D'Amico, M, Santoro, D, Londrino, F, Ravera, F, Ortisi, G & Sinico, RA 2016, 'Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)', Autoimmunity Reviews, vol. 15, no. 2, pp. 146-154. https://doi.org/10.1016/j.autrev.2015.10.004
Radice, Antonella ; Trezzi, Barbara ; Maggiore, Umberto ; Pregnolato, Francesca ; Stellato, Tiziana ; Napodano, Pietro ; Rolla, Davide ; Pesce, Gianpaola ; D'Amico, Marco ; Santoro, Domenico ; Londrino, Francesco ; Ravera, Federica ; Ortisi, Giuseppe ; Sinico, Renato Alberto. / Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). In: Autoimmunity Reviews. 2016 ; Vol. 15, No. 2. pp. 146-154.
@article{d548622df1e04e66bcb57ccfd3ced610,
title = "Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)",
abstract = "Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of idiopathic membranous nephropathy (IMN). They can differentiate IMN from other glomerular diseases and primary from secondary forms of MN. Preliminary data suggest that anti-PLA2R antibody titer correlates with disease activity but more solid evidence is needed.To evaluate the performance of anti-PLA2R antibody for monitoring nephropathy activity, 149 anti-PLA2R antibody measurements were performed during the follow-up of 42 biopsy proven IMN consecutive patients. Patients were enrolled either at time of diagnosis (33 cases, inception cohort) or after diagnosis (9 patients, non-inception cohort).Anti-PLA2R detection was performed using the highly sensitive transfected cell-based indirect immunofluorescence (IIFT).Over the follow-up there was a linear time-trend of decreasing proteinuria (P <0.001), increasing serum albumin (P <0.001) and decreasing PLA2R antibody levels (P = 0.002). There was a statistically significant association between changes in PLA2R antibody levels and the clinical course of PLA2R-positive IMN. The positive PLA2R serum antibody status was linearly associated with increasing proteinuria and decreasing serum albumin over time, compared with negative antibody status. Moreover, the strong correlation between the clinical conditions and PLA2R antibody levels allowed the prediction of prevalence distribution of patients with active disease, partial and complete remission. Over the course of the follow-up, the probability of halving proteinuria increased 6.5 times after disappearance of PLA2R antibodies.Our data suggest that the serial evaluation of anti-PLA2R antibodies could help in optimal timing and duration of the immunosuppressive therapy, reducing over(under)-treatment and associated side-effects.",
keywords = "Autoantibody, Biomarker, Membranous nephropathy, Phospholipase A2 receptor, Proteinuria",
author = "Antonella Radice and Barbara Trezzi and Umberto Maggiore and Francesca Pregnolato and Tiziana Stellato and Pietro Napodano and Davide Rolla and Gianpaola Pesce and Marco D'Amico and Domenico Santoro and Francesco Londrino and Federica Ravera and Giuseppe Ortisi and Sinico, {Renato Alberto}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.autrev.2015.10.004",
language = "English",
volume = "15",
pages = "146--154",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)

AU - Radice, Antonella

AU - Trezzi, Barbara

AU - Maggiore, Umberto

AU - Pregnolato, Francesca

AU - Stellato, Tiziana

AU - Napodano, Pietro

AU - Rolla, Davide

AU - Pesce, Gianpaola

AU - D'Amico, Marco

AU - Santoro, Domenico

AU - Londrino, Francesco

AU - Ravera, Federica

AU - Ortisi, Giuseppe

AU - Sinico, Renato Alberto

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of idiopathic membranous nephropathy (IMN). They can differentiate IMN from other glomerular diseases and primary from secondary forms of MN. Preliminary data suggest that anti-PLA2R antibody titer correlates with disease activity but more solid evidence is needed.To evaluate the performance of anti-PLA2R antibody for monitoring nephropathy activity, 149 anti-PLA2R antibody measurements were performed during the follow-up of 42 biopsy proven IMN consecutive patients. Patients were enrolled either at time of diagnosis (33 cases, inception cohort) or after diagnosis (9 patients, non-inception cohort).Anti-PLA2R detection was performed using the highly sensitive transfected cell-based indirect immunofluorescence (IIFT).Over the follow-up there was a linear time-trend of decreasing proteinuria (P <0.001), increasing serum albumin (P <0.001) and decreasing PLA2R antibody levels (P = 0.002). There was a statistically significant association between changes in PLA2R antibody levels and the clinical course of PLA2R-positive IMN. The positive PLA2R serum antibody status was linearly associated with increasing proteinuria and decreasing serum albumin over time, compared with negative antibody status. Moreover, the strong correlation between the clinical conditions and PLA2R antibody levels allowed the prediction of prevalence distribution of patients with active disease, partial and complete remission. Over the course of the follow-up, the probability of halving proteinuria increased 6.5 times after disappearance of PLA2R antibodies.Our data suggest that the serial evaluation of anti-PLA2R antibodies could help in optimal timing and duration of the immunosuppressive therapy, reducing over(under)-treatment and associated side-effects.

AB - Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of idiopathic membranous nephropathy (IMN). They can differentiate IMN from other glomerular diseases and primary from secondary forms of MN. Preliminary data suggest that anti-PLA2R antibody titer correlates with disease activity but more solid evidence is needed.To evaluate the performance of anti-PLA2R antibody for monitoring nephropathy activity, 149 anti-PLA2R antibody measurements were performed during the follow-up of 42 biopsy proven IMN consecutive patients. Patients were enrolled either at time of diagnosis (33 cases, inception cohort) or after diagnosis (9 patients, non-inception cohort).Anti-PLA2R detection was performed using the highly sensitive transfected cell-based indirect immunofluorescence (IIFT).Over the follow-up there was a linear time-trend of decreasing proteinuria (P <0.001), increasing serum albumin (P <0.001) and decreasing PLA2R antibody levels (P = 0.002). There was a statistically significant association between changes in PLA2R antibody levels and the clinical course of PLA2R-positive IMN. The positive PLA2R serum antibody status was linearly associated with increasing proteinuria and decreasing serum albumin over time, compared with negative antibody status. Moreover, the strong correlation between the clinical conditions and PLA2R antibody levels allowed the prediction of prevalence distribution of patients with active disease, partial and complete remission. Over the course of the follow-up, the probability of halving proteinuria increased 6.5 times after disappearance of PLA2R antibodies.Our data suggest that the serial evaluation of anti-PLA2R antibodies could help in optimal timing and duration of the immunosuppressive therapy, reducing over(under)-treatment and associated side-effects.

KW - Autoantibody

KW - Biomarker

KW - Membranous nephropathy

KW - Phospholipase A2 receptor

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84954399785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954399785&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2015.10.004

DO - 10.1016/j.autrev.2015.10.004

M3 - Article

VL - 15

SP - 146

EP - 154

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 2

ER -